Zeneca quashes rumours of Roche bid

Zeneca slammed the door on persistent takeover rumours yesterday as the former ICI drugs arm said it was not, and had not been, in discussions with Roche of Switzerland.

Market whispers had put the two companies together in a concerted campaign that had seen the pharmaceutical group's shares gyrate wildly in recent weeks. Yesterday's unequivocal denial of talks, which analysts believed could have led to a pounds 15bn bid by the giant Swiss group, saw Zeneca's shares fall 23p to 1,097p.

David Barnes, chief executive refused to comment further on bid talks as he announced a 44 per cent jump in pre-tax profits for the six months to June to pounds 506m. Despite the good figures, the market also worried about comments from Mr Barnes suggesting a slowdown in profits growth in the second half thanks to the cost of promoting new drugs.

He said: "We continue to face highly competitive markets in all our businesses. The group faces the exciting and demanding challenge of launching an unusually large number of new products. I am confident the returns from this near- term revenue investment programme will help secure Zeneca's future growth."

The big improvement in profits partly reflected a pounds 100m charge in the previous year's figures to fund a restructuring of Zeneca's speciality and agrochemicals businesses. Underlying profits were 12 per cent better after a 6 per cent rise in sales from pounds 2.38bn to pounds 2.53bn.

That included pharmaceuticals sales, which exceeded pounds 1bn for the first time in a six-month period as a 7 per cent volume increase was offset by a 1 per cent decline in prices as cuts, especially in Italy, continued to squeeze the industry.

Zeneca's older drugs, such as Tenormin, fell but the shortfall was more than made up by newer treatments. Sales of Diprivan, an anaesthetic, and cancer drug Zoladex grew at 21 per cent and 33 per cent respectively.

In Zeneca's other divisions, strong demand for herbicides drove a 17 per cent rise in profits from the agrochemicals operation. Rising raw materials prices squeezed the small speciality chemicals arm.

The company also remained tight-lipped about prospects for expanding its latest acquisition - 50 per cent of Salick, a US company that runs cancer clinics. Analysts believe the provision of care will be a profitable sideline for drugs companies, which face increasing pricing pressures in their core business.

Zeneca is, however, seen as less dependent on diversifications than many of its peers. It has a widely admired new drugs pipeline, including four treatments for cancer and a pill for asthma.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Recruitment Genius: Admin Assistant

£12000 - £15000 per annum: Recruitment Genius: An expanding Insurance Brokerag...

Ashdown Group: Editor-in-chief - Financial Services - City, London

£60000 - £70000 per annum + benefits : Ashdown Group: A highly successful, glo...

Guru Careers: Pricing Analyst

£30 - 35k (DOE): Guru Careers: We are seeking a Pricing Analyst with experienc...

Ashdown Group: Treasury Assistant - Accounts Assistant - London, Old Street

£24000 - £26000 per annum + benefits : Ashdown Group: A highly successful, glo...

Day In a Page

Revealed: Why Mohammed Emwazi chose the 'safe option' of fighting for Isis, rather than following his friends to al-Shabaab in Somalia

Why Mohammed Emwazi chose Isis

His friends were betrayed and killed by al-Shabaab
'The solution can never be to impassively watch on while desperate people drown'
An open letter to David Cameron: Building fortress Europe has had deadly results

Open letter to David Cameron

Building the walls of fortress Europe has had deadly results
Tory candidates' tweets not as 'spontaneous' as they seem - you don't say!

You don't say!

Tory candidates' election tweets not as 'spontaneous' as they appear
Mubi: Netflix for people who want to stop just watching trash

So what is Mubi?

Netflix for people who want to stop just watching trash all the time
The impossible job: how to follow Kevin Spacey?

The hardest job in theatre?

How to follow Kevin Spacey
Armenian genocide: To continue to deny the truth of this mass human cruelty is close to a criminal lie

Armenian genocide and the 'good Turks'

To continue to deny the truth of this mass human cruelty is close to a criminal lie
Lou Reed: The truth about the singer's upbringing beyond the biographers' and memoirists' myths

'Lou needed care, but what he got was ECT'

The truth about the singer's upbringing beyond
Migrant boat disaster: This human tragedy has been brewing for four years and EU states can't say they were not warned

This human tragedy has been brewing for years

EU states can't say they were not warned
Women's sportswear: From tackling a marathon to a jog in the park, the right kit can help

Women's sportswear

From tackling a marathon to a jog in the park, the right kit can help
Hillary Clinton's outfits will be as important as her policies in her presidential bid

Clinton's clothes

Like it or not, her outfits will be as important as her policies
NHS struggling to monitor the safety and efficacy of its services outsourced to private providers

Who's monitoring the outsourced NHS services?

A report finds that private firms are not being properly assessed for their quality of care
Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

The Tory MP said he did not want to stand again unless his party's manifesto ruled out a third runway. But he's doing so. Watch this space
How do Greek voters feel about Syriza's backtracking on its anti-austerity pledge?

How do Greeks feel about Syriza?

Five voters from different backgrounds tell us what they expect from Syriza's charismatic leader Alexis Tsipras
From Iraq to Libya and Syria: The wars that come back to haunt us

The wars that come back to haunt us

David Cameron should not escape blame for his role in conflicts that are still raging, argues Patrick Cockburn
Sam Baker and Lauren Laverne: Too busy to surf? Head to The Pool

Too busy to surf? Head to The Pool

A new website is trying to declutter the internet to help busy women. Holly Williams meets the founders